<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126069">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01916174</url>
  </required_header>
  <id_info>
    <org_study_id>NN9068-4026</org_study_id>
    <secondary_id>2012-005468-93</secondary_id>
    <secondary_id>U1111-1137-3809</secondary_id>
    <nct_id>NCT01916174</nct_id>
  </id_info>
  <brief_title>A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects</brief_title>
  <official_title>A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to assess the expected
      biological equivalence between two formulations of insulin degludec/liraglutide (IDegLira)
      with identical active ingredient in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Area under the serum IDeg concentration time curve after single dose</measure>
    <time_frame>Assessed from 0 to 120 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed serum IDeg concentration after single dose</measure>
    <time_frame>Assessed from 0-120 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma liraglutide concentration time curve after single dose</measure>
    <time_frame>Assessed from 0-72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma liraglutide concentration after single dose</measure>
    <time_frame>Assessed from 0-72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the serum IDeg concentration time curve after single dose</measure>
    <time_frame>Assessed from 0-120 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum IDeg concentration</measure>
    <time_frame>Assessed from 0-120 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life for IDeg after single dose</measure>
    <time_frame>Assessed from 0-120 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma liraglutide concentration time curve after single dose</measure>
    <time_frame>Assessed from 0-72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma liraglutide concentration after single dose</measure>
    <time_frame>Assessed from 0-72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life of liraglutide after single dose</measure>
    <time_frame>Assessed from 0-72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Insulin degludec/liraglutide, B5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomly allocated to the two single dose administrations (one for each of the two IDegLira formulations) on the two separate dosing visits. The two administration days will be separated by a wash-out period of 7-15 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin degludec/liraglutide, V2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomly allocated to the two single dose administrations (one for each of the two IDegLira formulations) on the two separate dosing visits. The two administration days will be separated by a wash-out period of 7-15 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin degludec/liraglutide</intervention_name>
    <description>Subject will receive a single injection (s.c.) of IDegLira B5</description>
    <arm_group_label>Insulin degludec/liraglutide, B5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin degludec/liraglutide</intervention_name>
    <description>Subject will receive a single injection (s.c.) of IDegLira V2</description>
    <arm_group_label>Insulin degludec/liraglutide, V2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female volunteers

          -  Body mass index (BMI) between 18.5 and 27.0 kg/m^2 (both inclusive)

          -  Body weight between 60 and 90 kg (both inclusive)

        Exclusion Criteria:

          -  Female of child-bearing potential who is pregnant, breast-feeding or intend to become
             pregnant or is not using adequate contraceptive methods. Adequate contraceptive
             measures are implants, injectables, combined oral contraceptives, hormonal
             intrauterine device, sexual abstinence or vasectomised partner

          -  History or presence of cancer, or any clinically significant cardiovascular,
             respiratory, metabolic, renal, hepatic, gastrointestinal, endocrine (incl. diabetes),
             haematological, dermatological, venereal, neurological, psychiatric diseases or other
             major disorders

          -  Use of any prescription or non-prescription medication, except for paracetamol,
             acetylsalicylic acid, contraceptives and vitamins (but including mega-dose vitamin
             therapy, as judged by the investigator) within 2 weeks before the trial

          -  Drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 7, 2013</lastchanged_date>
  <firstreceived_date>August 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
